IMMUCELL CORP DE
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
ICCC$10.22+4.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
PART I: FINANCIAL INFORMATION Unaudited Financial Statements Balance Sheets as of March 31, 2025 and December 31, 2024
Part 1. FINANCIAL INFORMATION
BALANCE SHEETS
| As of March 31, 2025 | As of December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $4,599,371 | $3,758,232 |
| Trade accounts receivable | 3,346,425 | 3,771,133 |
| Inventory | 7,357,366 | 7,112,623 |
| Prepaid expenses and other current assets | 616,477 | 400,762 |
| Total current assets | 15,919,639 | 15,042,750 |
| Property, plant and equipment, net | 25,019,259 | 25,349,019 |
| Operating lease right-of-use asset | 4,527,379 | 4,560,679 |
| Goodwill | 95,557 | 95,557 |
| Intangible assets, net | 14,328 | 19,104 |
| Other assets | 45,417 | 33,368 |
| TOTAL ASSETS | $45,621,579 | $45,100,477 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES: | ||
| Current portion of debt obligations | $1,516,230 | $1,497,619 |
| Current portion of operating lease liability | 380,958 | 432,072 |
| Accounts payable and accrued expenses | 1,968,565 | 2,482,522 |
| Total current liabilities | 3,865,753 | 4,412,213 |
| LONG-TERM LIABILITIES: | ||
| Debt obligations, net of current portion | 8,653,064 | 9,040,975 |
| Operating lease liability, net of current portion | 4,108,918 | 4,129,102 |
| Total long-term liabilities | 12,761,982 | 13,170,077 |
| TOTAL LIABILITIES | 16,627,735 | 17,582,290 |
| CONTINGENT LIABILITIES AND COMMITMENTS (See Note 10) | ||
| STOCKHOLDER’ EQUITY: | ||
| Common stock, $0.10 par value per share, 15,000,000 and 15,000,000 shares authorized, 9,045,924 and 9,042,392 shares issued and 8,982,623 and 8,979,091 shares outstanding, as of March 31, 2025 and December 31, 2024, respectively. | 904,593 | 904,240 |
| Additional paid-in capital | 40,944,476 | 40,916,155 |
| Accumulated deficit | (12,716,743) | (14,163,726) |
| Treasury stock, at cost, 63,301 shares as of both March 31, 2025 and December 31, 2024 | (138,482) | (138,482) |
| TOTAL STOCKHOLDERS’ EQUITY | 28,993,844 | 27,518,187 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $45,621,579 | $45,100,477 |
The accompanying notes are an integral part of these unaudited financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.